Argenica Therapeutics Limited

Argenica Therapeutics is a clinical-stage biotechnology company focused on the research, development, and commercialisation of neuroprotective therapeutics for stroke and other acute central nervous system injuries. The company's lead product candidate, ARG-007 (also referred to as xaranetide), is a cationic, arginine-rich peptide designed to protect brain cells and reduce cell death following ischaemic stroke, traumatic brain injury, and hypoxic ischaemic encephalopathy. Argenica was incorporated in 2019 based on research from the University of Western Australia and the Perron Institute for Neurological and Translational Science. The company has completed a Phase 1 clinical trial demonstrating safety and tolerability in healthy volunteers and is conducting a Phase 2 trial in acute ischaemic stroke patients in Australia. It is also preparing for a Phase 2b trial and addressing regulatory requirements with the US Food and Drug Administration to enable future clinical trials in the United States. The company intends for ARG-007 to be administered by first responders in the field to provide immediate neuroprotective treatment prior to hospital arrival.